INVEST IN HEALABLES

Personalized Tech to turn down pain & turn up performance

Play Video

“Pain shouldn’t be chronic, and people shouldn’t have to live with it”

Highlights

Things that differentiate Healables as an exceptional tech company

Market

People

TECH

Using our cutting-edge technology that is not only safe and effective but also simple to operate, our objective is to assist individuals in recovering from muscle strains and other physical sports injuries in a more expedient manner. And the crowdfunding campaign that we are currently running will enable us to do more of that.

Updates 

OUTSTANDING RESULTS IN THE FIELD

A company that breaks decades of marginalization in the entertainment industry.

12 Reasons To Invest in Healables Now

Investing in Healables is a smart choice
1. Our Team
64109c294b9306348134e914_639ac88554dd5481e58c7e7c_3-p-500.png

Moshe Lebowitz | CEO, Co-Founder

Moshe Lebowitz is a visionary who believes that humanity is on a positive trajectory and that we all have a responsibility to solve today’s biggest health challenges. He has previously served as UI/UX Designer, Product Manager and CEO. Lebowitz uses his rabbinic training to solve business problems differently and innovates through the creative integration of technology together with new inventions. Lebowitz practices Hasidic meditation and is trained in craniosacral therapy and Chinese medicine.

64109ccc9786bb3d280e9bd3_639ac88595df23298761ea1a_7-p-500.png

Dr. George Lowell | Chief Scientific Officer

Dr. George H. Lowell serves on the Board of Directors of BiondVax. He was Chief Scientific Officer for BioDefense at GSK Biologicals. He retired from the US Army as a Colonel where he initiated numerous clinical studies and clinical trials for FDA Approval. His academic posts include Visiting Scientist at Weizmann and Visiting Professor, Hebrew University-Hadassah Medical Center. Dr. Lowell is an early angel investor in Healables and serves on the BoD.

64109cfcd5f6e824ab92a6f4_639ac885508aef4260117bc4_2-p-500-1.png

Yehuda Barbasch | COO/CFO

Yehuda Barbasch has a background in international investment banking and has worked at Citibank and Pictet Wealth Management. His exceptional people skills, British accent and experience with all aspects of finance adds up to keen business planning and operational success. Yehuda holds a BBA in International Business from Leeds Beckett University and Aix-Marseille University and speaks English, French and Hebrew.

64109daba0571affa2a3d1b7_639ac884aff1d82d0c1077fa_4-p-500-1.png

Dr. Andrew Shiller, MD | Chief Medical Officer

Dr. Andrew David Shiller, MD Chief Medical Officer. Dr. Shiller earned his MD at Duke University’s School of Medicine, continuing at Harvard Medical School, with double residency training in Internal Medicine & Physical Medicine & Rehab. He completed fellowship training in Integrative Medicine at University of Maryland Center for Complementary Medicine Research. He studied & practiced natural healing and stress-reduction, along with nutrition, hands-on healing, movement therapy & mind/body awareness.

 

64109d3ca0571ad4ada3cc2e_639ac885a962432d024ac7c8_1-p-500.png

Ziv Ritchie | BSEE – CTO

Ziv Ritchie trained in Electrical Engineering at the Jerusalem College of Technology. He studied Reality Therapy at the William Glasser Institute and helped Professor Joshua Ritchie, MD found and manage the Refuah Institute, the leading provider of Torah-based coach training in the world. Ziv combines his technological knowledge and development skills with his psychological training to develop the Healables digital health coaching app and oversee the development and production of Healables electroceutical devices and textiles.

64109d9d210a9cac9a6eb924_639ac8850a971f06ce6f529e_5-p-500.png

Marco Van Der Putten Landau | CBDO

Marco van der Putten Landau is an international business development and marketing professional with the rare talent, ability and business acumen to add value and close deals by bringing people and businesses from all over the world together. Marco has lived in Europe, South America, China and Israel and is fluent in English, Spanish, French, Portuguese, Dutch, Italian and Chinese. Marco’s ability to understand and bridge cultural nuances empowers him to bring out the universal truths in the people that he works with and create business synergies and partnerships throughout the globe.

yasha-harari-portrait-2017-black-white.png

Yasha Harari | CMO

Yasha Harari is a marketing professional, having worked with a vast range of world class products and services. He has led marketing and driven record results for a variety of top B2B, B2C and B2B2C firms in the areas of medical devices, tech, gaming, FinTech, retail brands, trade associations, consumer goods, publishers, advertising companies, and many more, around the world. Yasha is responsible for pioneering significant Internet marketing gold standards used by people worldwide since decades.

 

2. Healables’ vision is to heal people with smart clothing instead of drugs.

Your dollars are not just going toward a good financial investment. Your investment goes towards helping improve the quality of life of mankind. It’s like an ESG investment.

The Problem

Worldwide, chronic pain impacts over 770 million people.[4]to do a clinical test. In the US, the CDC reports that approximately 20% of adults suffer from various forms of chronic pain [5]to do a clinical test. That’s an astonishing 60 million people! [6]to do a clinical test.

Current pain management options are often limited to:

Pain medication can have downsides such as addiction or other physical side-effects, which leaves a gap in treatment options.

The Center for Disease Control (CDC) recommends maximizing use of non-opioid therapies [6a]

The 2022 CDC Clinical Practice Guideline 6B, which is intended for clinicians prescribing opioids for adult outpatients with pain.

3. Healables’ Solution
“Wearables that Heal”

Healables has developed novel wearables that dock with smart textiles and connect with AI to personalize protocols so that every user can get exactly what they need.

The US Congress expands access to non-opioids

The NOPAIN Act [6c] was passed in an end-of-year legislative package in the 117th Congress in 2022. As a result of the law, patients and providers will have expanded access to non-opioids starting in 2025.
The Non-Opioids Prevent Addiction in the Nation Act (“NOPAIN Act”) is a policy that will prevent opioid addiction before it starts by increasing the use of non-opioid pain management approaches in outpatient surgical settings.
The Non-Opioids Prevent Addiction in the Nation Act (“NOPAIN Act”) is a policy that will prevent opioid addiction before it starts by increasing the use of non-opioid pain management approaches in outpatient surgical settings.
The NOPAIN Act will increase the use of non-opioid pain management approaches by changing outdated federal reimbursement policies.

Pain medication can have downsides such as addiction or other physical side-effects, which leaves a gap in treatment options.

The US Congress expands access to non-opioids

This NOPAIN Act will ensure that safe, non-addictive therapies are widely available to the tens of millions .[6d] of Americans who undergo an outpatient surgical procedure every year. Drug-related overdoses and deaths skyrocketed .[6e] during the COVID-19 pandemic resulting in the highest rates ever recorded. This policy change aims to reduce unnecessary exposure to opioids and the likelihood of opioid abuse or addiction following an acute pain incident.

4. LEAD PRODUCT & PRODUCT PIPELINE:

SPORTS/WELLNESS (CE) – ELECTROGEAR PRODUCT LINE

We provide physiotherapists and personal trainers with microcurrent devices, smart compression conductive garments (body sleeves, socks & shirts) and an app with an AI health coach to improve the function, the recovery & the performance of their sports & fitness clients. Note: Our wellness device does not require FDA certification prior to sale or distribution.

SPORTS/WELLNESS (CE) – ELECTROGEAR PRODUCT LINE

‍In Years 1-2: Treat arm, leg & back muscles, tendons, and joints to ameliorate chronic pain, accelerate healing, reduce inflammation, increase function and diminish NSAID/opioid pain med dependencies.

Note: Our 1st medical device will get an FDA exemption or have a 510k for typical sports- and musculoskeletal-related injuries and bruises.

‍Successful clinical trials and FDA approvals will allow us to enter the hospital and health insurance systems, thereby opening up the $2T global medical market for chronic pain & illness e.g., diabetic neuropathy and osteoarthritis.

5. Exciting Initial Data
88% of users showed 50% or greater pain relief that was often accompanied by the improved functional activity of the tissues affected.[7]

Healables Relieves Musculoskeletal Pains.

This graph details cases wherein our device was used to treat a variety of disorders: Musculoskeletal complaints involving the elbow, forearm, wrist, hand, knee, shoulder, or upper or lower back

Healables Reduces Inflammatory Pains.

This graph details cases wherein our device was used to treat a variety of disorders: Systemic complaints involving Fibromyalgia, Diabetic Neuropathy, Migraine, Respiratory, COPD And that’s a good reason to invest in. Healables.
6. Patented Technology
What is the technology? What are the tech breakthroughs we needed to invent in order to implement the solution?

We needed to invent the tech of dry electrodes, non contact electrodes, smart market textiles with stretchable electronics, miniaturized electronics, washability, biocompatibility, and the platform is designed to be future proofed and super charged with Artificial Intelligence.

We believe that this is the most advanced wearable therapeutic technology on the market today and it will only be more powerful when we combine the real world data sets from users with AI.

Why is the tech a good reason to invest?

Our patented tech can disrupt a broad range of verticals in multiple sectors, (ie: cosmetics, food tech, medical, veterinary, sports and wellness / fitness [7b] and automotive), and that is why it is a good reason to invest in Healables’ Patented Deep Technology.

7. Market Size & Investment Opportunity
We’re building the future of pain relief: Our cutting-edge wearable microcurrent technology will revolutionize the $6.91 Billion pain relief medtech market[8]

Our patented tech can disrupt a broad range of verticals in multiple sectors, (ie: cosmetics, food tech, medical, veterinary, sports and wellness / fitness7b, and automotive), and that is why it is a good reason to invest in Healables’ Patented Deep Technology.

‍Long-Range Market Opportunities: Total Addressable Market (TAM): $6.4T
Near-Term Primary Market Focus: Serviceable Addressable Market (SAM): $100.5B
The Big Opportunity: Serviceable Obtainable Market (SOM) & Earlyvangelists (EVG)
TAM = $6.4T
SAM = $100.5B
SOM & EVG = $1B
Competition
While there are several companies that may be considered competitors of Healables in some form, none of them on the market today delivers Healables’ combination of microcurrent, e-textiles, wearables, digital health coaching, AI and digital health telecommunications at an attractive price.
These competitors include:

Our patented tech can disrupt a broad range of verticals in multiple sectors, (ie: cosmetics, food tech, medical, veterinary, sports and wellness / fitness7b, and automotive), and that is why it is a good reason to invest in Healables’ Patented Deep Technology.

8. Timing

Our patented tech can disrupt a broad range of verticals in multiple sectors, (ie: cosmetics, food tech, medical, veterinary, sports and wellness / fitness7b, and automotive), and that is why it is a good reason to invest in Healables’ Patented Deep Technology.

The conditions are right now for electrotherapy

By getting in on the ground floor, Healables’ CrowdFunding investors can be a part of getting in on a movement of restoring humanity to a healthier state.

Healable has done an open label trial and has succeeded in demonstrating safety and usability, and because we are before the randomized controlled trial, this is your opportunity to get in and have the most upside.

9. Validation & Partnerships
10. Current Product

We introduced our sports product called ElectroGear at CES ‘22. We are launching it in Q2 of 2023.

As a wellness product, ElectroGear already has the CE mark, which is a mark of compliance with EU health, safety, and environmental standards. ElectroGear is dedicated towards enhancing sports performance and accelerating recovery in professional and amateur athletes.

Our flagship medical product is moving through the regulatory process to demonstrate that we can reduce inflammation, relieve pain and accelerate healing without medication.

As part of the Healables solution, wearable sensors will measure physiological signals that correlate with recovery, and improvement in mobility, agility, plus speed, powering and serving as the Key Performance Indicators (KPIs) that further validate ElectroGear as a premiere performance product.

Our smart textiles are comfortable. They can be worn at home or on the go without hanging wires. They include knee sleeves, arm sleeves, smart socks, caps, shoulder textiles, and smart shirts.

In our Sports & Wellness ElectroGear™ Product Line, we offer the first ready-to-use digital health remote treatment platform. It can be used within and outside the clinic or studio of the physical therapists and personal trainers improving function, recovery & performance of their sports and fitness clients.

Coupled with a digital health coach to transmit microcurrent protocols via wearable textile garments, this unique approach in the form of digital health protocols via an AI driven App runs a proprietary easy-to-use small electron stream device that docks with any of our smart textiles.

11. Business Model

Healables’ initial product line, ElectroGear sports performance and athletic recovery products, provides an early revenue stream.

At present, Healables utilizes a hybrid B2B device/SaaS business model focusing on B2B practitioners such as physical therapists, physios, personal trainers, athletic trainers, massage therapists and other body workers. Healables will be generating revenue in two different ways:

Currently, the ElectroGear device is available for pre-sale. Check out www.electrogear.com to learn more.

“Healables is also in discussions with a number of major corporations about licensing our technology for integration with their current products,” explains Lebowitz. “As the discussions are ongoing, we can’t reveal who they are until the deals are public. Sign up for our newsletter to be the first to know about updates when they happen.”

The sports performance and wellness market has enormous potential on its own[12] , yet it is dwarfed by the size of the MedTech opportunity.

The total addressable market in the MedTech space is projected to grow to $579 Billion by 2023.13 [13]

In the MedTech category, Healables’ intended applications include treatments for:

Healables platform technology is incredibly versatile. It can be deployed across multiple verticals along a number of product lines.

Initially, we’re addressing the wellness vertical through sports performance and we’re already selling in multiple countries.

In parallel, we’re working on fast-tracking the medical product line through the regulatory and reimbursement routes in the US, UK, and EU and are particularly interested in the DiGA legislation in Germany and Europe that reimburses digital health products that consumers can take home.

In addition to sports and medical verticals, our core technology can also be integrated into the cosmetic, veterinary and automotive verticals in the future.

When it comes to chronic pain, in Europe alone, the chronic pain management device market is estimated to be worth $1.45B by 2026. Additionally, the global sport/wellness market is upwards of $8B. The global medical market surpasses $2T, and the global electro-cosmetic/beauty market $50B.

11. Achieved & Upcoming Milestones

Soft-Launch, User Testing, Sports Pilot, Beta Testing, Clinical Trial

References

1 = Chronic Pain Market Outlook (2023 – 2033), Future Marketing Insights, https://www.futuremarketinsights.com/reports/chronic-pain-market

2,4 = Prescient & Strategic Intelligence, Chronic Pain Treatment Market Research Report https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market

3 = World’s Best Hospitals 2021, Newsweek, https://www.newsweek.com/best-hospitals-2021/israel
5 = The Global Burden Of Chronic Pain, Tracy P. Jackson, M.D.; Victoria Sutton Stabile, B.A.; K.A. Kelly McQueen, M.D., M.P.H. ASA Newsletter June 2014, Vol. 78, 24–27. https://pubs.asahq.org/monitor/article-abstract/78/6/24/3059/The-Global-Burden-Of-Chronic-Pain?redirectedFrom=fulltext

6 = 31 Chronic Pain Statistics: US & Global Prevalence, LAURA SMITH, Associate Editorial Manager, https://www.thegoodbody.com/chronic-pain-statistics/

6a = Prescribing Opioids for Pain — The New CDC Clinical Practice Guideline, Deborah Dowell, M.D., M.P.H., Kathleen R. Ragan, M.S.P.H., Christopher M. Jones, Pharm.D., Dr.P.H., Grant T. Baldwin, Ph.D., M.P.H., and Roger Chou, M.D., New England Journal of Medicine (NEJM), https://www.nejm.org/doi/full/10.1056/NEJMp2211040
6b = CDC Clinical Practice Guideline for Prescribing Opioids for Pain  United States, 2022, Deborah Dowell, M.D., M.P.H., Kathleen R. Ragan, M.S.P.H., Christopher M. Jones, Pharm.D., Dr.P.H., Grant T. Baldwin, Ph.D., M.P.H., and Roger Chou, M.D., National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639433/
6c = NOPAIN Act, Voices For Non Opioid Choices, https://nonopioidchoices.org/nopain-act/
6d = New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults, National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information, https://pubmed.ncbi.nlm.nih.gov/28403427/
6e = Overdose Deaths Accelerating During COVID-19, Center for Disease Control and Prevention, https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
7 = Healables compendium, Dr. Shiller, Dr. Ehrenberg, Dr. Lowell, Healables internal data
7b = The Six Reasons The Fitness Industry Is Booming, Forbes, https://www.forbes.com/sites/benmidgley/2018/09/26/the-six-reasons-the-fitness-industry-is-booming/?sh=7625abaa506d
8 = Pain Management Devices Market, Grand View Research, https://www.grandviewresearch.com/industry-analysis/pain-management-devices-market
8a – Pain Management Devices Market Size, Share & Trends Analysis Report By Product (RFA, Neurostimulation), By Application (Neuropathic Pain, Cancer), By Region (APAC, North America), And Segment Forecasts, 2022 – 2030, https://www.grandviewresearch.com/press-release/global-connected-health-wellness-devices-market
9 = Statista, Wellness and Spa, https://www.statista.com/topics/1336/wellness-and-spa/#topicOverview
10= S.586 – NOPAIN Act, Sponsor: Sen. Capito, Shelley Moore [R-WV] (Introduced 03/04/2021), https://www.congress.gov/bill/117th-congress/senate-bill/586/text

11 = H.R.3259 – NOPAIN Act, Sponsor: Rep. Sewell, Terri A. [D-AL-7] (Introduced 05/14/2021), https://www.congress.gov/bill/117th-congress/house-bill/3259/text?format=txt

12 = IN CASE YOU MISSED IT:CAPITO’S NO PAIN ACT TO ADDRESS OPIOID CRISIS SIGNED INTO LAW, U.S. Senator Shelley Moore Capito (R-W.Va.), https://www.capito.senate.gov/news/press-releases/in-case-you-missed-itcapitos-no-pain-act-to-address-opioid-crisis-signed-into-law
12b = Sports Medicine Market Size to Reach USD 10270 Million by 2027 at a CAGR of 7.5% | Valuates Reports PR Newswire, https://www.prnewswire.com/news-releases/sports-medicine-market-size-to-reach-usd-10270-million-by-2027-at-a-cagr-of-7-5–valuates-reports-301388619.html
13 = Statista, Medical Technology, https://www.statista.com/outlook/hmo/medical-technology/worldwide#

$0

raised from 0 investors

Min $250

Pre-Market Valuation: $29.27M

If you invest, you’re betting Healables will be worth more in the future.

Dr. George Lowell, Colonel, U.S. Army (Ret.), BioTech Investor, Board Member, BiondVax, Former Chief Scientific Officer for BioDefense at GSK Biologicals, Early Seed Investor in Healables
“We have taken on a vital mission, to achieve faster healing and pain relief for people suffering from chronic pain. It’s a great feeling to know your product helps people. Join me today, and become a Healables investor, so that together, we can build a future without pain.”
Invested this round & previously
TOTAL RAISED Pre-CrowdFunding:
$1.2 Million